[Effect of delta-sleep inducing peptide on the functional activity of some organs and tissues of rats during physiological aging].
Bondarenko. T I TI; Maĭboroda. E A EA; Mikhaleva. I I II; Prudchenko. I A IA
Key Findings
- Monthly sub‑cutaneous DSIP (100 mg/kg) for five days showed a hepatoprotective effect in aging rats.
- DSIP did not alter pancreatic function in the same animals.
- DSIP was not involved in regulating calcium homeostasis during physiological aging.
Practical Outcomes
- The study suggests DSIP might have liver‑protective properties in the context of aging, but the dose used is far higher than what humans could safely take. There is no evidence it benefits pancreas health or calcium balance, and no clear protocol for human use emerges from this work.
Summary
In rats, giving a high dose of delta‑sleep inducing peptide (DSIP) under the skin each month for five days helped protect the liver as the animals got older, but it didn’t change how the pancreas worked or affect calcium balance.
Abstract
The authors show that exogenous delta-sleep inducing peptide (DSIP) injected subcutaneously to the rats in the age of 2-24 months of postnatal development in a dose of 100 mg/kg of animal body weight in courses for 5 consecutive days every month, has a hepatoprotective effect. DSIP does not affect the functional activity of the pancreas, and is not involved in the regulation of calcium homeostasis in the physiological aging of the organism.
Study Information
pubmed
2012